Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity Journal Article


Authors: Daman, A. W.; Antonelli, A. C.; Redelman-Sidi, G.; Paddock, L.; Khayat, S.; Ketavarapu, M.; Cheong, J. G.; Jurado, L. F.; Benjamin, A.; Jiang, S.; Ahimovic, D.; Lawless, V. R.; Bale, M. J.; Loutochin, O.; McPherson, V. A.; Divangahi, M.; Niec, R. E.; Pe'er, D.; Pietzak, E.; Josefowicz, S. Z.; Glickman, M. S.
Article Title: Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity
Abstract: Mycobacterium bovis Bacillus Calmette-Guérin (BCG) is the vaccine against tuberculosis and an immunotherapy for bladder cancer. When administered intravenously, BCG reprograms bone marrow hematopoietic stem and progenitor cells (HSPCs), leading to heterologous protection against infections. Whether HSPC reprogramming contributes to the anti-tumor effects of BCG administered into the bladder is unknown. We demonstrate that BCG administered in the bladder colonizes the bone marrow and, in both mice and humans, reprograms HSPCs to alter and amplify myelopoiesis. BCG-reprogrammed HSPCs are sufficient to confer augmented anti-tumor immunity through production of neutrophils, monocytes, and dendritic cells that broadly remodel the tumor microenvironment, drive T cell-dependent anti-tumor responses, and synergize with checkpoint blockade. We conclude that bladder BCG acts systemically through hematopoiesis, highlighting the broad potential of HSPC reprogramming to enhance the innate drivers of T cell-dependent tumor immunity. © 2025 Elsevier Inc.
Keywords: bladder cancer; immunotherapy; epigenetics; tumor immunity; hematopoiesis; bcg; innate immune memory; trained immunity
Journal Title: Cancer Cell
ISSN: 1535-6108
Publisher: Cell Press  
Publication status: Online ahead of print
Date Published: 2025-01-01
Online Publication Date: 2025-01-01
Language: English
DOI: 10.1016/j.ccell.2025.05.002
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics